Tags:BioTechDevelopmentLifeMedicalMedTechPharmacy
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
Location: United States, Massachusetts, Boston
Member count: 51-200
Total raised: $53M
Founded date: 2001

Investors 3

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
04.05.2007-$53M-venturebea...

Mentions in press and media 5

DateTitleDescriptionCategoryAuthorSource
04.11.2019AVEO Oncol...The FDA said that if the compa...--medcitynew...
31.01.2019FDA stiff-...→ Aveo On­col­o­gy was hit wit...-Endpoints ...endpts.com...
23.06.2017Mer­ck KGa...→ Cladrib­ine is back. Once gi...-Emma Yasin...endpts.com...
04.05.2007Cancer-dru...Aveo Pharmaceuticals, a Cambri...--venturebea...
-AVEO Oncol...BOSTON--(BUSINESS WIRE)--Mar 1...--oaoa.com/n...